Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Plexxikon selects Clinipace to manage 4 clinical trials for RA treatment

Clinipace Worldwide, a global digital clinical research organization, announced today that Plexxikon Inc., a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease, has selected Clinipace to manage all aspects of four clinical trials comprising a Phase 1 healthy volunteer study, a Phase 1b rheumatoid arthritis study, and two phase 2 oncology studies.

16 Mar 2011

Nuclear fallout-related health fears rise in Japan

Concerns regarding health risks "rose dramatically in Japan Tuesday" after officials said more radiation was released at a nuclear power plant that was damaged in the tsunami, the Associated Press reports. In an address to the nation, Prime Minister Naoto Kan said radiation had been emitted from four reactors. "The level seems very high, and there is still a very high risk of more radiation coming out," he said.

16 Mar 2011

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

Patients with earlier stage high-risk Chronic Lymphocytic Leukemia recently began receiving a new combination treatment in a Phase I/II clinical trial that researchers believe could result in a more effective therapy for this disease, Biothera announced today.

15 Mar 2011

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

COMFORT-II, the second pivotal Phase III trial of Incyte Corporation's investigational Janus kinase inhibitor, ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis, when compared to best available therapy.

15 Mar 2011

OncoSec signs agreement with Inovio to purchase non-DNA cancer vaccine technology

OncoSec Medical Inc., a developer of innovative and proprietary medical approaches to treat solid tumor cancers with unmet medical needs, announced today that it has signed an agreement with Inovio Pharmaceuticals, Inc. providing for the purchase by OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

15 Mar 2011

WHO reports on risk from radiation exposure, Humanitarian Assistance arrives in Japan following earthquake

The WHO on Saturday said the public health risk of a radiation leak resulting from earthquake damage at a nuclear reactor site in Japan "appeared to be 'quite low' but the WHO network of medical experts was ready to assist if requested," Reuters reports.

15 Mar 2011

CTI, Chroma enter agreement to co-develop and license tosedostat

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced today that the companies have entered into a co-development and license agreement providing CTI with exclusive marketing and co-development rights to Chroma's drug candidate tosedostat in North, Central and South America.

14 Mar 2011

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the 12 months ended December 31, 2010, and provided a business update.

11 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

American Botanical Council honors excellence in herbal medicine

The 6th Annual American Botanical Council Celebration and Awards Ceremony took place last night, honoring individuals and companies who influence the present and future of the herbal medicine movement. The ABC event is part of the annual Natural Products Expo West trade show and Nutracon scientific conference, held in Anaheim, California.

11 Mar 2011

OncoVista plans to advance reduced-toxicity targeted cancer treatments

OncoVista Innovative Therapies, Inc., reported in a letter to shareholders that it is moving forward on its business plan to develop targeted, safer and more efficacious cancer treatments with reduced or no toxicity.

11 Mar 2011

Research: CREBBP mutation may help cancer resist steroid treatment, fuel ALL's return

Despite dramatically improved survival rates for childhood acute lymphoblastic leukemia, relapse remains a leading cause of death from the disease. Work led by St. Jude Children's Research Hospital investigators identified mutations in a gene named CREBBP that may help the cancer resist steroid treatment and fuel ALL's return.

10 Mar 2011

Caltech students receive Lemelson-MIT Prize for innovative disease diagnostic technology works

California Institute of Technology graduate student Guoan Zheng is the recipient of the 2011 $30,000 Lemelson-MIT Caltech Student Prize.

10 Mar 2011

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

Predictive Biomarker Sciences (PBS-Bio) has uncovered how the experimental drug UNBS1450, produced by Unibioscreen, kills cancer cells.

10 Mar 2011

Novel sortase-based techniques allow modification of a large variety of different proteins

Whitehead Institute scientists have created a method that site-specifically modifies proteins to exert control over their properties when administered therapeutically. The technique should be useful to increase potency, slow metabolism, and improve thermal stability of therapeutically useful proteins, such as interferon alpha 2 (IFN-alpha 2), which is used to treat variety of diseases, including leukemia, melanoma, and chronic hepatitis C.

10 Mar 2011

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

Stemline Therapeutics, Inc. today announced that SL-401, the Company's lead compound, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

10 Mar 2011

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

ERYtech Pharma announces the early completion of the enrollment and safety follow-up a Phase II clinical trial for GRASPA. This open-labeled trial introduced GRASPA in a first-line treatment for Acute Lymphoblastic Leukemia in patients older than 55 years.

9 Mar 2011

Fluidigm fourth quarter revenue increases to $10.4 million

Fluidigm Corporation today announced its financial results for the fourth quarter and full year ended December 31, 2010.

9 Mar 2011

NHMRC awards $38.4M for cancer and blood cell research

Institute research into how cancer develops and blood cell production and function will today be awarded $38.4 million under the National Health and Medical Research Council's (NHMRC) program grants scheme.

9 Mar 2011

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon today announced that it has treated the first patient in a Phase 2 clinical trial in Hodgkin lymphoma with PLX3397. This novel agent is an oral, selective inhibitor that down-modulates two key cell types that are thought to mediate the progression of Hodgkin lymphoma tumors — macrophages and mast cells.

8 Mar 2011

Leukemia News and Research

Further Reading

Plexxikon selects Clinipace to manage 4 clinical trials for RA treatment

Nuclear fallout-related health fears rise in Japan

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

OncoSec signs agreement with Inovio to purchase non-DNA cancer vaccine technology

WHO reports on risk from radiation exposure, Humanitarian Assistance arrives in Japan following earthquake

CTI, Chroma enter agreement to co-develop and license tosedostat

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

American Botanical Council honors excellence in herbal medicine

OncoVista plans to advance reduced-toxicity targeted cancer treatments

Research: CREBBP mutation may help cancer resist steroid treatment, fuel ALL's return

Caltech students receive Lemelson-MIT Prize for innovative disease diagnostic technology works

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

Novel sortase-based techniques allow modification of a large variety of different proteins

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

Fluidigm fourth quarter revenue increases to $10.4 million

NHMRC awards $38.4M for cancer and blood cell research

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News